Senior Correspondent, London
Ben's Feed
Jun 24, 2014
Jun 23, 2014
Jun 23, 2014

Shire flags new drugs in AstraZeneca-style defence to AbbVie

LONDON, June 23 (Reuters) – Shire flagged the
promise of existing and new drugs on Monday as evidence that
AbbVie’s $46 billion offer undervalued the company, the
latest British firm to be targeted by a U.S. group seeking lower
taxes.

Shire is taking a leaf out of AstraZeneca’s playbook
by disclosing long-range internal forecasts – a tactic used
successfully by its larger London-listed rival in fending off a
$118 billion bid from Pfizer.

Jun 23, 2014

Bayer bets on gene therapy with Dimension deal

FRANKFURT/LONDON (Reuters) – Bayer has struck an alliance with U.S. biotech firm Dimension Therapeutics to develop a gene therapy for the treatment of haemophilia A, marking renewed interest in an approach to tackle the cause of diseases at a cellular level.

Gene therapy involves inserting corrective genes into malfunctioning cells to get them to work again without further use of drugs. Dimension has been looking into using viruses to carry the genes to the affected cells.Gene therapy has seen more than 20 years of experiments and a series of disappointments. However, Amsterdam-based UniQure is about to start selling its gene therapy drug Glybera in Europe as a treatment for the ultra-rare disease lipoprotein lipase deficiency (LPLD) with partner Chiesi.

Jun 23, 2014
Jun 23, 2014

Shire to set out AstraZeneca-style defence against AbbVie

LONDON (Reuters) – Shire is to take a leaf out of AstraZeneca’s playbook by giving long-range forecasts for its drugs as it seeks to convince shareholders that AbbVie’s $46 billion offer undervalues the business.

Flemming Ornskov, Shire’s chief executive, will update investors on prospects for key medicines on Monday afternoon, mirroring the approach of disclosing long-range internal forecasts used by fellow London-listed drugmaker AstraZeneca in its successful defence against Pfizer.

Jun 19, 2014
Jun 18, 2014

French biotech Cellectis surges as Pfizer signs cancer drug deal

June 18 (Reuters) – U.S. drugmaker Pfizer, which
failed last month in a $118 billion bid to buy AstraZeneca
, said on Wednesday it had signed a deal with French
biotech Cellectis to develop immunotherapy drugs in
cancer.

The news sent shares in Cellectis surging 50 percent higher,
valuing the company, which was founded in 1999, at around 195
million euros ($264 million).

Jun 17, 2014
Jun 17, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben